CorMedix (CRMD) vs DBV Technologies S.A. (DBVT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
CorMedix (CRMD) has outperformed DBV Technologies S.A. (DBVT) over the past year, losing 28.7% versus a loss of 46.6%. Over five years, CRMD leads with a +52.8% price change compared with -18.0% for DBVT. DBV Technologies S.A. is the larger company by market cap ($568.8 million vs $565.9 million), about 1.0 times the size, while CorMedix is growing revenue faster (+617.0% vs +35.8%).
CorMedix converts more of its revenue into profit, with a net margin of 52.3% versus -2607.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRMD | DBVT |
|---|---|---|
| Share price | $7.26 | $9.05 |
| Market cap | $565.88M | $568.78M |
| 1-day change | -2.68% | -0.66% |
| YTD return | -37.58% | -52.79% |
| 1-year return | -28.68% | -46.61% |
| 5-year return | +52.84% | -18.03% |
| P/E ratio (TTM) | 3.54 | — |
| Forward P/E | 20.74 | — |
| EPS (TTM) | $2.05 | $-3.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $311.71M | $5.64M |
| Revenue growth (YoY) | +617.03% | +35.77% |
| Net income (latest FY) | $163.06M | $-146.95M |
| Gross margin | 88.46% | — |
| Operating margin | 48.17% | -2609.23% |
| Net margin | 52.31% | -2607.29% |
| 52-week high | $13.02 | $26.19 |
| 52-week low | $6.13 | $8.63 |
| Distance from 52-week high | -44.24% | -65.44% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +111.16% | +328.07% |
| Average volume | 1.11M | 350.73K |
| Shares outstanding | 77.94M | 62.85M |
| Employees | 191 | 170 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRMD has outperformed DBVT by 17.9 percentage points over the past year.
- CorMedix is more profitable, keeping 52.3 cents of every revenue dollar as net income versus -2607.3 cents for DBV Technologies S.A..
- CorMedix grew revenue faster in its latest fiscal year (+617.03% vs +35.77%).
About CorMedix
CRMD stock →CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure.
Healthcare · Biotechnology · 191 employees
About DBV Technologies S.A.
DBVT stock →DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Healthcare · Biotechnology · 170 employees
CRMD vs DBVT FAQ
Which is bigger, CorMedix or DBV Technologies S.A.?
DBV Technologies S.A. (DBVT) is larger, with a market capitalization of $568.78M compared with $565.88M for CorMedix (CRMD).
Which stock has performed better over the past year, CRMD or DBVT?
CRMD returned -28.68% over the past 12 months, compared with -46.61% for DBVT (price return, excluding dividends). Past performance does not predict future results.
Are CorMedix and DBV Technologies S.A. in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.